Gland Pharma (NSE:GLAND) EBIT per Share : ₹70.34 (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma EBIT per Share?

Gland Pharma's EBIT per Share for the three months ended in Mar. 2024 was ₹18.71. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ₹70.34.

During the past 12 months, the average EBIT per Share Growth Rate of Gland Pharma was 12.50% per year. During the past 3 years, the average EBIT per Share Growth Rate was -7.60% per year. During the past 5 years, the average EBIT per Share Growth Rate was 7.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Gland Pharma's EBIT per Share or its related term are showing as below:

NSE:GLAND' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -7.6 Med: 15.8 Max: 39.4
Current: -7.6

During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Gland Pharma was 39.40% per year. The lowest was -7.60% per year. And the median was 15.80% per year.

NSE:GLAND's 3-Year EBIT Growth Rate is ranked worse than
72.86% of 866 companies
in the Drug Manufacturers industry
Industry Median: 7.25 vs NSE:GLAND: -7.60

Gland Pharma's EBIT for the three months ended in Mar. 2024 was ₹3,082 Mil.

Gland Pharma EBIT per Share Historical Data

The historical data trend for Gland Pharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma EBIT per Share Chart

Gland Pharma Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EBIT per Share

Get a 7-Day Free Trial

61.19

84.52

98.58

64.49

70.34

Gland Pharma Quarterly Data
	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															6.88	16.16	17.96	17.52	18.71

Gland Pharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Gland Pharma's EBIT per Share for the fiscal year that ended in Mar. 2024 is calculated as

	EBIT per Share		(A: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	11587.42	/	164.739
=	70.34

Gland Pharma's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	3081.88	/	164.743
=	18.71

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹70.34

Gland Pharma (NSE:GLAND) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Gland Pharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of Gland Pharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Gland Pharma (NSE:GLAND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (NSE:GLAND) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

543245:India

Address

Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307

Website

https://www.glandpharma.com

Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Further, the group is involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma (NSE:GLAND) Headlines

No Headlines